⇚ Regimen BALVERSA® - for Locally Advanced or Metastatic Urothelial Carcinoma Medical Name BALVERSA® (Erdafitinib) for Locally Advanced or Metastatic Urothelial Carcinoma with susceptible FGFR3 or FGFR2 genetic alterations Cycles Given N/A Delivery Phases N/A Special Instructions Monitor for hyperphosphatemia, hypercalcemia, ocular disorders and liver function abnormalities. The recommended starting dose of BALVERSA® is 8 mg orally once daily, with a dose increase to 9 mg once daily based on serum phosphate levels and tolerability at 14-21 days. Treatment should continue until disease progression or unacceptable toxicity occurs. References Siefker-Radtke AO, et al. JCO 2018 - VIEW External References http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.4503 - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration BALVERSA® (Erdafitinib) PO 9 mg Daily N/A N/A N/A N/A